Home > Blog > Multiple Sclerosis Treatment Cost in India (2026): Care Options, Hospitals & Patient Journey

Multiple Sclerosis Treatment Cost in India (2026): Care Options, Hospitals & Patient Journey

Filters & Insights

MS treatment in India: DMT costs $1,500–$25,000/year, Ocrevus available, diagnostics $800–$2,500. Advanced care guide

A diagnosis of multiple sclerosis changes everything suddenly there is a chronic condition to manage, medications to understand, and a future that feels uncertain. For international patients, a second question quickly follows: can they access good MS care in India, and what will it realistically cost over time?

India offers advanced MS management — diagnosis, disease-modifying therapy (DMT), relapse treatment, and rehabilitation — at significantly lower cost than the USA, UK, or Germany. Initial diagnostic workup typically costs $800–$2,500; annual DMT costs range from $1,500–$25,000 depending on the therapy; and a structured relapse or rehabilitation admission runs $2,000–$8,000. India’s top neurology centres now have access to high-efficacy therapies including Ocrevus (Ocrelizumab), which only became available in India in late 2023.

This guide covers what MS treatment actually involves, what it costs for international patients, and how to plan for ongoing care.

Want to understand your Multiple Sclerosis treatment options?

Connect with our team on WhatsApp for personalized assistance.

Table of Contents

Understanding Multiple Sclerosis: What Patients Need to Know First

Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks myelin the protective coating around nerve fibres in the brain and spinal cord. When myelin is damaged, nerve signals slow down or are disrupted entirely. Over time, scar tissue forms in multiple places throughout the central nervous system, giving the disease its name.

MS is not one condition it behaves very differently depending on its type, the areas of the brain and spinal cord affected, and the individual. This is why treatment is not one-size-fits-all and why cost estimates for “MS treatment” vary so widely.

Types of MS and What They Mean for Treatment

MS Type	What Happens	Proportion of Patients	Treatment Approach
Relapsing-Remitting MS (RRMS)	Distinct attacks or relapses followed by full or partial recovery periods.	About 85% at diagnosis	Disease-modifying therapies (DMTs) to reduce relapses; corticosteroids may be used for acute relapses.
Secondary Progressive MS (SPMS)	Begins as RRMS and gradually changes into ongoing neurological worsening, with or without relapses.	May develop in many RRMS patients over time	Selected DMTs for active disease, symptom control, physiotherapy, rehabilitation, and supportive care.
Primary Progressive MS (PPMS)	Steady worsening of neurological function from the beginning, without clearly defined relapses.	About 10–15%	Limited DMT options, including ocrelizumab for eligible patients; rehabilitation and symptom management are important.
Clinically Isolated Syndrome (CIS)	A first episode of neurological symptoms suggestive of MS, but not yet sufficient to confirm a diagnosis.	Varies	MRI and risk assessment; DMT may be considered to delay or reduce the chance of conversion to definite MS.

The earlier MS is treated, the better the long-term outcome. Research consistently shows that patients who begin DMT promptly after diagnosis have fewer relapses, slower disease progression, and better quality of life over decades.

Recognising MS: When to Seek a Specialist

MS most commonly first appears between ages 20 and 40. Symptoms depend on which part of the nervous system is affected and include:

Blurred, double, or temporary loss of vision (optic neuritis — often the first symptom)
Numbness or tingling in limbs, face, or trunk
Muscle weakness, particularly in the legs
Balance and coordination problems
Fatigue — often disproportionate and a hallmark of MS
Urinary urgency or incontinence
Cognitive difficulties (memory, concentration, word-finding)
Lhermitte’s sign: an electric shock sensation down the spine when bending the neck

Any episode of neurological symptoms lasting more than 24 hours — particularly if vision is involved — warrants urgent neurological assessment. Early diagnosis prevents delayed treatment and better protects long-term function.

How MS Is Diagnosed

There is no single diagnostic test for MS. Diagnosis follows the McDonald Criteria, which require evidence of demyelinating lesions separated in space and time within the central nervous system.

The workup typically includes:

Brain and spinal cord MRI — the most important investigation; shows demyelinating plaques, active inflammation, and lesion burden
Lumbar puncture (CSF analysis) — looks for oligoclonal bands, which are present in approximately 90% of MS patients
Evoked potentials testing — measures the speed of electrical signals in visual, auditory, and sensory pathways
Blood tests — to rule out conditions that mimic MS (neuromyelitis optica spectrum disorder, vitamin B12 deficiency, Lyme disease, vasculitis)

All of these are available at major neurology centres in India.

MS Treatment Options Available in India

MS management has three distinct goals: reducing relapse frequency and severity (disease modification), treating acute relapses, and managing symptoms with rehabilitation. All three are available at India’s specialist neurology centres.

Want to know whether treatment in India is right for you? Request a free consultation today

Disease-Modifying Therapies (DMTs)

DMTs are the cornerstone of MS treatment. They do not cure MS or reverse existing damage, but they substantially reduce the number of relapses, slow lesion accumulation on MRI, and, for many patients, delay disability progression. Starting them early — at diagnosis rather than waiting for disability to accumulate — produces the best long-term outcomes.

DMTs are broadly categorised by efficacy and mechanism:

First-line / moderate-efficacy DMTs (oral and injectable):

Interferon beta products (Avonex, Rebif, Betaferon) — weekly or three-times-weekly injections
Glatiramer acetate (Copaxone) — daily or three-times-weekly injection
Dimethyl fumarate (Tecfidera) — oral, twice daily
Teriflunomide (Aubagio) — oral, once daily
Fingolimod (Gilenya) — oral, once daily

High-efficacy therapies (HETs) — infusion-based:

Natalizumab (Tysabri) — monthly IV infusion; blocks immune cell entry into the CNS
Ocrelizumab (Ocrevus) — 6-monthly IV infusion; the only drug approved for both RRMS and PPMS; launched in India in December 2023
Rituximab — used off-label for MS in India; B-cell depleting infusion every 6 months
Alemtuzumab (Lemtrada) — annual infusion courses; highly effective but significant side effect monitoring required
Cladribine (Mavenclad) — oral, taken in short annual courses

Important clinical note: High-efficacy therapies are not reserved for patients who have already tried and failed first-line therapy. Evidence strongly supports early use of high-efficacy DMTs in patients with active, aggressive MS. International patients should discuss this with their neurologist before defaulting to less effective options. As of 2025, only around 10% of MS patients in India access high-efficacy therapies — but access at specialist private centres is available for those who require it.

Acute Relapse Management

A relapse is a new or worsening neurological symptom lasting at least 24 hours. Relapses are treated with:

High-dose IV methylprednisolone — typically 1g per day for 3–5 days; reduces inflammation and shortens relapse duration
Oral steroid taper — for less severe relapses in some cases
Plasma exchange (plasmapheresis) — for severe relapses that do not respond to steroids

Symptom Management

MS symptoms are managed alongside DMT and rehabilitation:

Symptom	Common Management Approach
Fatigue	Energy-conservation strategies, structured rest, sleep assessment, graded activity, and selected medicines such as amantadine or modafinil when clinically appropriate.
Spasticity	Physiotherapy, stretching, positioning, and medicines such as baclofen or tizanidine. Intrathecal baclofen pumps may be considered for severe, treatment-resistant spasticity.
Bladder Dysfunction	Bladder training, fluid planning, medicines such as anticholinergics, intermittent catheterisation when needed, and urology review for persistent symptoms.
Pain and Neuropathic Symptoms	Neuropathic pain medicines such as gabapentin, pregabalin, or amitriptyline, alongside physiotherapy, sleep support, and pain-specialist review where needed.
Depression	Psychological support, counselling, cognitive behavioural therapy, social support, and antidepressants such as SSRIs when prescribed by a clinician.
Cognitive Difficulties	Cognitive rehabilitation, memory and attention strategies, structured cognitive therapy programmes, occupational therapy, and management of fatigue, mood, and sleep issues.

MS Rehabilitation in India

Rehabilitation is not optional for MS patients — it is where function is maintained and quality of life protected.

Physiotherapy addresses the physical consequences of MS — weakness, balance, spasticity, and gait problems. Regular structured physiotherapy maintains walking ability and reduces fall risk. Programmes are tailored to the patient’s current function and fatigue profile.

Occupational Therapy helps patients adapt their home and work environment, teaches energy conservation techniques, and provides adaptive equipment that allows independent daily living despite weakness or coordination problems.

Speech and swallowing therapy addresses bulbar symptoms — slurred speech and difficulty swallowing — which occur in more advanced or brainstem-affecting disease.

Cognitive rehabilitation targets attention, working memory, processing speed, and word-finding — common but often underrecognised MS symptoms. Compensatory strategies developed in therapy translate directly to improved daily functioning.

Specialist MS rehabilitation programs at India’s major centres combine all of the above in structured inpatient or intensive outpatient programs. International patients typically access 2–4 week intensive programs before returning home with a continuing care plan.

Multiple Sclerosis Treatment Cost in India: A Realistic Breakdown

This is the most misrepresented section in all competitor MS content. MS is a chronic disease — costs are not a single surgical package. They accumulate across diagnosis, ongoing DMT, relapse management, and regular monitoring. Below is an honest breakdown for international patients.

Critical pricing note: Domestic Indian sources show Rs. 3–17 lakh for “MS treatment” — these reflect either a single hospitalisation or severely underrepresented medication costs for Indian residents. International patient pricing at accredited private hospitals is substantially higher. All figures below are based on cross-referenced medical tourism platform data and should be verified with partner hospitals before travel.

Initial Diagnostic Workup

Investigation	Cost (USD) — International Patient
Neurologist Consultation (Initial)	$80 – $200
Brain MRI with Contrast	$250 – $500
Spinal Cord MRI	$200 – $400
Lumbar Puncture and CSF Analysis	$200 – $400
Evoked Potentials (VEP, SSEP, BAEP)	$150 – $350
Blood Tests Panel (Full MS Workup)	$150 – $300
Total Diagnostic Workup	$800 – $2,500

Annual DMT Costs in India (International Patients)

This is where the largest variation exists and where competitor content consistently fails — presenting a single bundled number that means nothing for the specific drug a patient needs.

DMT Category	Annual Cost (USD) — India International Patient	Notes
Injectable First-Line DMTs Interferon Beta, Glatiramer Acetate	$1,500 – $5,000 / Year	Generic versions may be available. Usually considered lower-efficacy options compared with newer high-efficacy therapies.
Oral Moderate-Efficacy DMTs Dimethyl Fumarate, Teriflunomide, Fingolimod	$3,000 – $10,000 / Year	Cost depends on brand, dose, monitoring requirements, and availability of generic alternatives.
Natalizumab (Tysabri) Monthly Infusion	$8,000 – $18,000 / Year	Includes regular infusion-facility charges. Requires careful monitoring, including assessment of PML risk.
Ocrelizumab (Ocrevus) 6-Monthly Infusion	$12,000 – $25,000 / Year	High-efficacy therapy. Cost may include infusion, pre-medication, and monitoring; availability varies by centre and supply.
Rituximab Off-Label, 6-Monthly Infusion	$4,000 – $10,000 / Year	Often lower cost than ocrelizumab. Used off-label for MS in some clinical settings based on neurologist assessment.
Alemtuzumab (Lemtrada)	$15,000 – $30,000 / Year for Initial Courses	Usually administered as two annual treatment courses, followed by prolonged safety monitoring and regular blood tests.

Important context: In the USA, Ocrevus costs approximately $80,000–$90,000 per year before insurance. In India, the international patient price of $12,000–$25,000 per year is substantially lower, with no waiting period and no prescribing criteria gatekeeping.

Rituximab used off-label for MS is a critical option for international patients — it costs significantly less than Ocrevus ($4,000–$10,000/year vs $12,000–$25,000) while delivering comparable B-cell depletion efficacy according to extensive real-world data. This decision should be made in consultation with a specialist MS neurologist.

Acute Relapse Hospitalisation

Treatment	Cost (USD) — International Patient
IV Methylprednisolone (3–5 Days)	$800 – $2,000
Hospital Stay — General Ward (Per Day)	$80 – $180
Plasma Exchange / Plasmapheresis (5–7 Sessions)	$3,000 – $6,000
Typical Uncomplicated MS Relapse Admission	$1,500 – $4,000

Inpatient MS Rehabilitation Program

Program	Cost (USD) — International Patient
Intensive Inpatient Rehabilitation (2 Weeks)	$2,500 – $6,000
Intensive Inpatient Rehabilitation (4 Weeks)	$5,000 – $10,000
Outpatient Physiotherapy (Per Session)	$25 – $60

Annual Monitoring Costs

Item	Annual Cost (USD)
Follow-Up Neurology Consultations (2–4 Per Year)	$200 – $600
Annual Brain and Spinal Cord MRI	$400 – $800
Blood Monitoring (CBC, LFTs, JCV Antibody and Other Required Tests)	$200 – $500
Annual Monitoring Total	$800 – $1,900

Cost Comparison: India vs Other Countries

Factor	India	USA	UK (Private)	Germany	Turkey
Ocrevus / Ocrelizumab (Annual)	$12,000 – $25,000	$80,000 – $90,000	£45,000 – £70,000	€40,000 – €65,000	$15,000 – $30,000
MRI (Brain + Spine)	$400 – $900	$3,000 – $6,000	£1,500 – £3,500	€1,500 – €3,000	$500 – $1,200
Neurologist Consultation	$80 – $200	$300 – $600	£200 – £500	€150 – €400	$80 – $200
Waiting Time for Specialist	Days – Weeks	Weeks – Months	Weeks – Months (NHS)	Weeks	Days – Weeks
English-Speaking Care	Yes — Major Hospitals	Yes	Yes	Partial	Partial

India’s cost advantage is most significant for high-efficacy DMT — the drugs most likely to meaningfully change long-term MS outcomes.

Want to know whether treatment in India is right for you? Request a free consultation today

Advanced MS Treatments in India

Autologous Haematopoietic Stem Cell Transplantation (AHSCT)

AHSCT is reserved for highly active, treatment-resistant RRMS — patients who have not responded to multiple DMTs and continue to accumulate disability. It is not a standard first or second-line treatment.

The procedure harvests the patient’s own stem cells, administers chemotherapy to reset the immune system, and reinfuses the stem cells. In carefully selected patients, published trial data (including MIST trial results) show it can produce sustained remission and significant disability improvement.

A small number of centres in India perform AHSCT for MS. Costs range from $20,000–$30,000, substantially below the $100,000–$200,000 charged in Western countries. Patient selection criteria are strict — most MS patients are not candidates, and the procedure carries significant risks. Referral for AHSCT assessment should always come from a specialist MS neurologist.

Multidisciplinary MS Clinics

India’s best MS centres operate multidisciplinary clinics combining neurologist, neurophysiologist, physiotherapist, occupational therapist, psychologist, and specialist MS nurse. This model — standard at major European and North American MS centres — is available at tier-1 hospitals in Delhi, Mumbai, Chennai, and Bengaluru.

Best Hospitals for MS Treatment in India

Delhi NCR

AIIMS (All India Institute of Medical Sciences), Delhi — the most experienced public-sector neurology department in India; extensive MS expertise; limited international patient infrastructure but clinically outstanding.

Medanta — The Medicity (Gurugram) — dedicated neurology department; access to all major DMTs including high-efficacy therapies; JCI accredited; strong international patient services.

Fortis Memorial Research Institute (Gurugram) — active MS management program; good international coordination.

Max Super Speciality Hospital, Saket — strong neurology team; infusion therapies available; well-organised for international patients.

Learn about treatment costs, hospitals, and care options tailored to your condition.

Living Well with MS

Work: Many people with MS continue working for years. Flexible schedules, remote work, rest breaks, and simple workplace accommodations can help manage fatigue and cognitive symptoms.
Exercise: Regular exercise improves strength, balance, mood, and fatigue. Walking, swimming, yoga, cycling, and light resistance training are often suitable. Avoid overheating and follow a physiotherapist-guided plan.
Diet: No diet cures MS. A balanced anti-inflammatory diet with vegetables, whole grains, oily fish, and less processed food supports overall health. Vitamin D may be advised by your neurologist.
Pregnancy: MS does not reduce fertility or usually affect pregnancy outcomes. Relapses often reduce during pregnancy but may increase after delivery. Discuss medication planning with your neurologist before conception.
Mental Health: Depression, anxiety, and emotional changes are common and treatable. Medication, counselling, and peer support can help.
Travel: Flying is generally safe. Carry enough medication, prescriptions, medical letters, emergency contacts, and plan rest breaks while avoiding excessive heat.

Why Early Treatment Matters

Without appropriate treatment, MS may lead to more frequent relapses, mobility problems, vision loss, cognitive decline, and progressive disability. Early use of suitable disease-modifying therapy can improve long-term outcomes.

Myths vs Facts About Multiple Sclerosis

Myth: MS is always rapidly disabling. Fact: Many people with MS live full, independent lives for decades after diagnosis. Disease course is highly variable. With effective DMT and good follow-up, many patients have minimal disability even 20–30 years after diagnosis. Rapid disability progression is the exception, particularly in patients who receive timely high-efficacy treatment.

Myth: MS cannot be treated. Fact: While MS is not curable, it is highly treatable. More than 20 DMTs are now approved globally. High-efficacy therapies reduce relapse rates by up to 70–80% compared to placebo in clinical trials. The treatment landscape has transformed dramatically in the last 15 years.

Myth: People with MS cannot work. Fact: The majority of MS patients remain employed. Work accommodations, flexible arrangements, and effective symptom management allow most people with mild to moderate MS to maintain professional careers.

Myth: Exercise worsens MS. Fact: The opposite is true. Structured exercise is beneficial — it improves fatigue, strength, balance, and mood in MS. This has been established by robust clinical research. The main practical consideration is avoiding overheating, not avoiding activity.

Myth: MS only affects movement. Fact: MS can affect virtually any neurological function — vision, balance, bladder, cognition, mood, and sexual function. Many of the most disabling symptoms are invisible: fatigue, pain, and cognitive difficulty are common but not apparent to observers.

How International Patients Access MS Treatment in India

MS treatment planning is different from planning for surgery — it requires thinking about both the initial visit and ongoing management after returning home.

Initial Visit: Diagnosis and Treatment Initiation

A first visit typically spans 2–4 weeks and covers:

Comprehensive diagnostic workup (MRI, CSF, evoked potentials)
Specialist MS neurologist assessment and diagnosis confirmation
DMT selection and initiation (first infusion if high-efficacy therapy chosen)
Rehabilitation assessment and initial intensive sessions

Ongoing Care Planning

For patients continuing DMT in India with periodic visits: Infusion therapies (Ocrevus every 6 months; Natalizumab monthly) can be timed to India visits. Annual MRI monitoring at the treating hospital. Teleconsultation with Indian neurologist between visits.

For patients sourcing DMT locally after initiation in India: Full written treatment plan on discharge including drug name, dose, monitoring schedule, and red-flag symptoms. Remote teleconsultation follow-up 3-monthly.

How Shifam Health Helps

Medical records and MRI reviewed by specialist neurologist before travel
Written cost estimates for diagnostic workup, DMT options, and rehabilitation
Hospital invitation letter for the Indian medical visa
Airport coordination and accommodation assistance
Dedicated coordinator throughout the hospital stay
Interpreter services in Arabic, Bangla, Swahili, and other languages
Structured teleconsultation follow-up after return home

We are compensated by our partner hospitals. There is no charge to patients for coordination.

Frequently Asked Questions About MS Treatment in India

What is the cost of multiple sclerosis treatment in India for international patients?

MS costs depend on what you need. Initial diagnostic workup: $800–$2,500. Annual DMT costs range from $1,500 (first-line injectable) to $25,000 (Ocrevus). A relapse hospitalisation: $1,500–$4,000 typically. Intensive 4-week rehabilitation: $5,000–$10,000. These are international patient ranges — domestic Indian prices are substantially lower and not relevant for your planning.

Can international patients receive MS treatment in India?

Yes. Major neurology centres offer MS diagnosis, DMTs, infusion therapy, relapse care, rehabilitation, and international patient support.

Is MS curable?

No, but modern disease-modifying therapies can reduce relapses and help preserve neurological function.

Which MS treatments are available in India?

Major centres offer Ocrevus, Natalizumab, Rituximab, Alemtuzumab, Fingolimod, Dimethyl fumarate, and other DMTs.

How is MS diagnosed?

Diagnosis uses MRI, CSF analysis, evoked potentials, and the McDonald Criteria.

How often are MRI scans needed?

Usually yearly, or every 6 months after a relapse or treatment change.

Which city is best for MS treatment?

Delhi NCR has broad specialist and DMT access. Mumbai and Chennai also have strong MS centres.

Is AHSCT available in India?

Yes, at select centres for carefully chosen patients with highly active, treatment-resistant MS.

Can MS patients have children?

Yes. Pregnancy planning is important because some MS medicines must be stopped before conception.

Is insurance accepted?

Some private hospitals accept international insurance. Coverage should be confirmed with the insurer and hospital before travel.

How can I get an MS specialist opinion?

Share MRI scans, neurology reports, medication history, and relapse details for specialist review

Related Neurology Resources

If you are exploring Multiple Sclerosis treatment in India, these resources may help you make informed decisions about hospitals, specialists, treatment options, and long-term neurological care:

Best Neurosurgery Hospitals in India (2026): Discover leading centers offering advanced neurology, neuroimmunology, and rehabilitation services.
https://shifamhealth.com/best-neurosurgery-hospitals-india-2026/
Best Neurosurgeons in India: Learn about India’s leading neurological specialists and multidisciplinary neuroscience teams.
https://shifamhealth.com/best-neurosurgeons-in-india/
Precision Medicine in Indian Neurology: Explore how personalized medicine and advanced diagnostics are improving outcomes for complex neurological disorders, including Multiple Sclerosis.
https://shifamhealth.com/precision-medicine-indian-neurology/
Pediatric Neurology Treatment in India: Understand specialized neurological care for children with complex neurological and autoimmune conditions.
https://shifamhealth.com/pediatric-neurology-treatment-india-epilepsy-autism/
Cost of Neurosurgery in India for International Patients: Compare neurological treatment costs and understand healthcare expenses for international patients seeking care in India.
https://shifamhealth.com/cost-of-neurosurgery-in-india-for-international-patients/

India offers access to experienced neurologists, advanced MRI diagnostics, disease-modifying therapies (DMTs), rehabilitation programs, and comprehensive long-term MS management at a fraction of the cost in many Western countries.

To receive a personalized treatment recommendation and cost estimate, share your MRI scans, neurological reports, and treatment history with us on WhatsApp. Our specialists will review your case and provide guidance within 48 hours.